Patrick English advises clients on merger control matters, particularly involving the healthcare industry and premerger notification analysis.

Mr. English leverages a particular knowledge and passion for the healthcare industry and a nuanced understanding of the regulatory space to guide companies — especially those in the pharmaceutical, life sciences, and medical device sectors — on:

  • Merger control proceedings before the Federal Trade Commission and Department of Justice
  • Premerger notification analysis, including under the Hart-Scott-Rodino Act
  • Internal investigations and compliance programs

He helps clients strategically navigate an evolving antitrust regulatory landscape, while evaluating risk and anticipating issues before they compromise a transaction. Mr. English devises creative solutions that allow his clients’ commercial visions to become reality.

A recognized leader both within the firm and in his field, Mr. English has served on Latham’s Recruiting Committee, as Local Co-Leader and Global Co-Leader of the LGBTQ+ Affinity Group, and on the Pro Bono Committee. Over the last decade serving in the American Bar Association’s Antitrust Section, he has been Co-Chair of the Membership, Diversity & Inclusion (MD&I) Committee and supported the Section’s Mentoring and Law Student Ambassador programs. In addition, Patrick has served as the leader of the Section’s LGBTQ+ Squad, a Vice Chair of MD&I Committee, a Vice Chair of the Health Care and Pharmaceuticals Committee, and as Young Lawyer Representative for the Health Care and Pharmaceuticals Committee.

He maintains a significant and varied pro bono practice involving multiple areas, including immigration, Social Security benefits, expungements, and human rights. Mr. English also serves as Whitman-Walker Health pro bono liaison at Latham. He is a longstanding advocate for Whitman-Walker, having previously held roles as Co-Chair of both the Whitman Walker Health Walk to End HIV Legal Community Campaign and the Steering Committee for Whitman-Walker’s Going the Extra Mile event.  In addition to his pro bono work, Mr. English was elected to the D.C. Bar Board of Governors in 2023.

Before law school, Mr. English spent three years with the Federal Trade Commission (FTC) in its Bureau of Competition, where he focused on mergers in the healthcare and life sciences sectors. He has also served as a Research Fellow for the American Antitrust Institute.

Mr. English’s experience includes representing:


  • Amgen in acquiring Teneobio, a clinical-stage biotechnology company
  • Amneal Pharmaceuticals in its US$1.4 billion business combination with Impax Laboratories
  • ANI Pharmaceuticals in obtaining US antitrust clearance to acquire Novitium, a pharmaceuticals company specializing in niche generic products
  • ArchiMed Group in acquiring Natus Medical, a medical device solutions provider
  • Arthrocare in its US$1.7 billion merger with Smith & Nephew
  • Cerner in acquiring Kantar Health, a life sciences and research company
  • Gavis Pharmaceuticals in its US$880 million sale to Lupin
  • Grail, an American biotechnology company, in its sale to Illumina
  • Integra LifeSciences Holdings in its US$1.05 billion acquisition of Johnson & Johnson’s Codman Neurosurgery business
  • Vitamin Shoppe in its US$50 million acquisition of Super Supplements

Other Merger Control Matters

  • Cannery Casino Resorts in selling two Las Vegas properties to Boyd Gaming
  • Entercom Communications in its US$105 million acquisition of Lincoln Financial Media
  • Leap Wireless in its US$1.2 billion sale to AT&T
  • Veyance Technologies in its US$1.9 billion acquisition by Continental AG

Bar Qualification

  • District of Columbia


  • JD, Northwestern University School of Law, 2009
    cum laude
  • MBA, Kellogg School of Management, 2009
  • BA, University of Virginia, 2003